Skip to main content

Table 5 Adverse events of the case group and control group

From: Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study

AEs

Case group, n(%)

Control group, n(%)

χ2

P

Anemia

 Any grade

48(87.27)

63(75.90)

2.717

0.099

  ≥ 3

4(7.27)

6(7.23)

0.000

1.000

WBC decreased

 Any grade

22(40.00)

32(38.55)

0.029

0.865

  ≥ 3

2(3.64)

4(4.82)

0.000

1.000

Neutropenia

 Any grade

17(30.91)

25(30.12)

0.010

0.921

  ≥ 3

2(3.64)

6(7.23)

0.262

0.609

Thrombocytopenia

 Any grade

2(3.64)

6(7.23)

0.262

0.609

  ≥ 3

0(0.00)

2(2.41)

–

0.517

Hypokalemia

 Any grade

17(30.91)

2(2.41)

22.630

0.000

  ≥ 3

7(12.73)

0(0.00)

8.642

0.003

ALT increased

 Any grade

11(20.00)

11(13.25)

1.124

0.289

  ≥ 3

4(7.27)

2(2.41)

0.894

0.345

AST increased

 Any grade

4(7.27)

4(4.82)

0.054

0.817

  ≥ 3

2(3.64)

1(1.20)

0.132

0.717

Urea nitrogen increased

 Any grade

7(12.73)

7(8.43)

0.669

0.413

  ≥ 3

0(0.00)

0(0.00)

–

–

Diarrhea

 Any grade

53(96.36)

22(26.51)

65.065

0.000

  ≥ 3

14(25.45)

1(1.20)

20.079

0.000

Nausea

 Any grade

36(65.45)

55(66.27)

0.010

0.922

  ≥ 3

0(0.00)

0(0.00)

–

–

Vomiting

 Any grade

28(50.91)

41(49.40)

0.030

0.862

  ≥ 3

3(5.45)

6(7.23)

0.004

0.951

Asthenia

 Any grade

31(56.36)

37(44.58)

1.838

0.175

  ≥ 3

0(0.00)

0(0.00)

–

–

Rash

 Any grade

13(23.64)

15(18.07)

0.633

0.426

  ≥ 3

0(0.00)

2(2.41)

–

0.517

Pigmentation

 Any grade

19(34.55)

29(34.94)

0.002

0.962

  ≥ 3

0(0.00)

0(0.00)

–

–

Hand-foot syndrome

 Any grade

8(14.55)

15(18.07)

0.296

0.586

  ≥ 3

0(0.00)

1(1.20)

–

1.000

Alopecia

 Any grade

48(87.27)

77(92.77)

1.172

0.279

  ≥ 3

0(0.00)

0(0.00)

–

–

Stomatitis

 Any grade

18(32.73)

23(27.71)

0.399

0.528

  ≥ 3

4(7.27)

5(6.02)

0.000

1.000